Research Capsules

December 2008
Pharmaceutical Representative;Dec2008, Vol. 38 Issue 12, p11
Product Review
The article evaluates several pharmaceutical drug products which includes Liraglutide from Novo Nordisk AS, Selzentry from Pfizer Inc., and Vyvanse from Shire Pharmaceutical Group PLC.


Related Articles

  • New Products.  // Drug Topics;6/16/2008, Vol. 152 Issue 7, p54 

    The article evaluates several drugs including Advair Diskus 250/50 inhalation powder from GlaxoSmithKline, Vyvanse from Shire, and NovoSeven RT recombinant drug from Novo Nordisk.

  • CDM Princeton. Arnold, Matthew // Medical Marketing & Media;Jul2009, Vol. 44 Issue 7, p48 

    The article focuses on the healthcare advertising firm CDM Princeton. It states that the company has not only survived a consolidation that wiped out 40% of its business but was able to win enough new business to more than account for the loss. The agency has won assignments from companies...

  • Novo-Nordisk 2nd to abandon effort for inhaled insulin. Long, Don // Biomedical Business & Technology;Feb2008, Vol. 31 Issue 2, p14 

    The article reports that Novo-Nordisk ceased its inhaled insulin project. The company doubted that the inhaled insulin market would be profitable. The withdrawal is expected to result to lay-offs at Novo-Nordisk's California site. The company turned skeptical about the marketability of inhaled...

  • ETHICAL PRODUCTS.  // Australian Journal of Pharmacy;Sep2012, Vol. 93 Issue 1108, p52 

    The article evaluates several drugs including Victoza from Novo Nordisk A/S, Azilect from Lundbeck A/S and Bronchitol from Pharmaxis Ltd.

  • Best Use of Public Relations.  // Medical Marketing & Media;Nov2012 Awards, p13 

    The article announces that the Best Use of Public Relations Gold Award and Silver Award have been given to the Viagra: Anti-Counterfeit campaign from RAPP Ltd. and Pfizer Inc. and the campaign from Novo Nordisk A/S. respectively.

  • Court report.  // Medical Device Daily;12/12/2007, Vol. 11 Issue 225, p5 

    The article reports that Novo Nordisk has settled a lawsuit against Pfizer claiming that Pfizer's product Exubera infringed patents owned by Novo Nordisk. The lawsuit was filed in the U.S. Federal Court in the Southern District of New York in August 2006. The patents are for inhaled insulin...

  • Another blow for inhaled protein therapeutics. Opar, Alisa // Nature Reviews Drug Discovery;Mar2008, Vol. 7 Issue 3, p189 

    The article discusses the future implications of targeting the lung for delivering protein therapeutics in the light of the setbacks in the development of inhaled insulin products. The author highlights the reasons why Novo Nordisk discontinued the development of its fast-acting inhaled insulin...

  • FDA actions in brief.  // Formulary;Oct2005, Vol. 40 Issue 10, p322 

    Reports on U.S. Food and Drug Administration actions regarding various drugs. Approval of an influenza vaccine from GlaxoSmithKline; Approval of a combination vaccine from Merck; Approval of an insulin aspart injection from Novo Nordisk; Approval of atorvastatin from Pfizer.

  • ALGERIA: A Regional Champion Coming of Age.  // Pharmaceutical Executive;Dec2014, Vol. 34 Issue 12, pS2 

    The article reports on the performance of the pharmaceutical industry in Algeria. It is stated that Algeria has the second largest pharmaceuticals market in Africa, worth nearly 3 billion dollars; and with a population of 38 million, and a high GDP, Algeria is worth making investments in the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics